PegBio Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 53

Employees

  • Stock Symbol
  • 02565

Stock Symbol

  • Share Price
  • $0.41
  • (As of Friday Closing)

PegBio General Information

Description

PegBio Co Ltd is engaged in the discovery and development of therapies. The company's main product PB-119, is a self-developed, obtained marketing approval from the National Medical Products Administration (NMPA) and entered commercialization preparation stage, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309.

Contact Information

Website
www.pegbio.com
Formerly Known As
Paige Biomedical (Suzhou), PegBio Biomedical (Suzhou), PegBio (Suzhou), Pige Biopharmaceutical (Suzhou)
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Room 606, Building 1, Haozhang Building
  • Gongshu District
  • Hangzhou, Zhejiang 900000
  • China
+86 0571
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
HKG
Vertical(s)
Manufacturing, Life Sciences, Oncology
Corporate Office
  • Room 606, Building 1, Haozhang Building
  • Gongshu District
  • Hangzhou, Zhejiang 900000
  • China
+86 0571

PegBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PegBio Stock Performance

As of 13-Nov-2026, PegBio’s stock price is $0.41. Its current market cap is $173M with 418M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.41 $0.43 $0.39 - $9.90 $173M 418M 10.4M -$0.12

PegBio Financials Summary

As of 30-Jun-2026, PegBio has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 205,101 3,431,151
Revenue 0 0 0 0
EBITDA (47,465) (28,674) (38,904) (39,434)
Net Income (47,287) (28,974) (39,462) (39,435)
Total Assets 74,220 85,645 29,912 51,922
Total Debt 22,465 13,379 13,903 9,721
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PegBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PegBio‘s full profile, request access.

Request a free trial

PegBio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore PegBio‘s full profile, request access.

Request a free trial

PegBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
PegBio Co Ltd is engaged in the discovery and development of therapies. The company's main product PB-119, is a self-dev
Biotechnology
Hangzhou, China
53 As of 2026

Campbell, CA
 

Pudong, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PegBio Competitors (2)

One of PegBio’s 2 competitors is Vivus, a Corporate Backed or Acquired company based in Campbell, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vivus Corporate Backed or Acquired Campbell, CA
Hua Medicine Formerly VC-backed Pudong, China
You’re viewing 2 of 2 competitors. Get the full list »

PegBio Patents

  • 31

    Total Documents Applications and Grants

  • Total Patents Families

  • 18

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

PegBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026092369-A1 Circular rna molecule and use thereof Pending 31-Oct-2024
WO-2024017379-A1 Preparation method for polyethylene glycol conjugate of active polypeptide or protein Inactive 22-Jul-2022
EP-4406548-A1 Pharmaceutical composition containing pegylated exenatide variant and use thereof Pending 24-Sep-2021
EP-4406548-A4 Pharmaceutical composition containing pegylated exenatide variant and use thereof Pending 24-Sep-2021
US-20250152721-A1 Pharmaceutical composition containing pegylated exenatide variant and use thereof Pending 24-Sep-2021 A61K47/60
To view PegBio’s complete patent history, request access »

PegBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PegBio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PegBio‘s full profile, request access.

Request a free trial

PegBio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view PegBio’s complete esg history, request access »

PegBio FAQs

  • When was PegBio founded?

    PegBio was founded in 2008.

  • Where is PegBio headquartered?

    PegBio is headquartered in Hangzhou, China.

  • What is the size of PegBio?

    PegBio has 53 total employees.

  • What industry is PegBio in?

    PegBio’s primary industry is Biotechnology.

  • Is PegBio a private or public company?

    PegBio is a Public company.

  • What is PegBio’s stock symbol?

    The ticker symbol for PegBio is 02565.

  • What is the current stock price of PegBio?

    As of 13-Nov-2026 the stock price of PegBio is $0.41.

  • What is the current market cap of PegBio?

    The current market capitalization of PegBio is $173M.

  • Who are PegBio’s competitors?

    Vivus and Hua Medicine are competitors of PegBio.

  • What is PegBio’s annual earnings per share (EPS)?

    PegBio’s EPS for 12 months was -$0.12.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process